Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US (Q37164594)
Jump to navigation
Jump to search
scientific article published on 02 September 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US |
scientific article published on 02 September 2013 |
Statements
1 reference
Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US (English)
1 reference
Timothy Juday
1 reference
Todd Correll
1 reference
Ayanna Anene
1 reference
Michael S Broder
1 reference
Jesse Ortendahl
1 reference
Tanya Bentley
1 reference
1 reference
1 September 2013
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference